AEROECLIPSE*

July 6, 2017

Trudell Medical International: Providing patient-focused solutions and reducing health system costs: Our journey in the global fight against COPD

Chronic Obstructive Pulmonary Disease (COPD) is a significant healthcare problem, with an estimated 384 million cases worldwide in 2010.Population aging is predicted to drive further growth, with one study forecasting a 150% increase in prevalence overall, and up to 220% in the 75 and over age group, between 2010 and 2030.2

 

January 1, 2016

Study Summary: AeroEclipse* BAN

The AeroEclipse* II BAN is the most significant advancement in the history of small volume nebulizers, generating aerosol only in response to the patient's inspiratory maneuver. Since virtually no aerosol is produced during exhalation or at rest, clinicians can be confident that the dose prescribed is the dose delivered.